Clinical Report: Axpaxli Could Transform Wet AMD Care

Overview

The phase 3 SOL-1 trial demonstrated that Axpaxli significantly outperformed the FDA-approved anti-VEGF therapy Eylea in treating neovascular age-related macular degeneration (nAMD). This landmark study suggests a potential shift in treatment paradigms for wet AMD, with implications for patient care and regulatory pathways.

Background

Neovascular age-related macular degeneration (nAMD) is a leading cause of vision loss in older adults, traditionally treated with anti-VEGF therapies. Current treatment regimens often require frequent injections, which can lead to treatment burden and suboptimal outcomes. The development of Axpaxli, a bioresorbable intravitreal hydrogel, aims to provide a more durable treatment option, potentially improving patient adherence and visual outcomes.

Data Highlights

Key Findings

• Axpaxli outperformed Eylea in the SOL-1 trial, marking the first superiority trial success in this field.
• Two-thirds of patients receiving Axpaxli were rescue-free at week 52.
• Axpaxli demonstrated stable OCT measurements, indicating effective disease control.
• The trial was designed in accordance with FDA guidelines, ensuring a streamlined regulatory pathway.
• Both components of Axpaxli are individually FDA approved, facilitating a faster filing process.

Clinical Implications

The results from the SOL-1 trial may lead to a paradigm shift in the management of nAMD, offering a treatment option that reduces the frequency of injections and enhances patient outcomes. Clinicians should consider the potential of Axpaxli in their treatment plans, especially for patients struggling with the current anti-VEGF regimens.

Conclusion

Axpaxli represents a significant advancement in the treatment of wet AMD, with the potential to improve patient care through enhanced efficacy and reduced treatment burden. Ongoing monitoring of its regulatory approval and clinical integration will be essential.

References

1. Retinal Physician, 2026 -- Axpaxli Superior to Aflibercept in Wet AMD Trial
2. Ophthalmology Management, 2025 -- Ocular Therapeutix to Accelerate NDA Submission for Axpaxli in Wet AMD
3. Retinal Physician, 2026 -- Axpaxli Data Presented at Macula Society Meeting
4. Ophthalmology Management, 2026 -- Ocular Therapeutix Presented Positive Phase 3 Axpaxli Data at Macula Society Meeting
5. Oregon Health & Science University -- Age-Related Macular Degeneration Preferred Practice Pattern®
6. PubMed -- Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE)
7. Retinal Physician, 2026 -- Axpaxli Could Transform Wet AMD Care
8. Age-Related Macular Degeneration Preferred Practice Pattern® - Oregon Health & Science University
9. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials - PubMed
10. Axpaxli Could Transform Wet AMD Care | Retinal Physician